We’ve announced our first CTA submission, advancing TGM-312 for MASH into the clinic. Discovered in-house and backed by robust preclinical data, TGM-312 shows potential as a truly differentiated treatment option for people living with MASH. Find out more: https://t.co/UePz2J72OA

Our GalOmic siRNA, TGM-312 for the treatment of MASH, has shown outstanding data in Gubra’s highly translatable GAN DIO-MASH model and is now advancing toward a CTA submission in Q4 2025. If you're at #TIDESEurope, attend our presentation to find out more.

Find out more here: https://t.co/O2TKQgqUEM #RNAi #AI #Biotech #RelentlessMedicineDiscovery

e-therapeutics has relaunched as Tangram Therapeutics and simultaneously unveiled our next-generation AI platform LLibra OS. We're poised to unlock the true promise of RNAi medicines as we progress towards the clinic by the end of 2025.

We've announced significant progress on ETX-312, our lead GalOmic therapy for MASH: ✅ Positive non-clinical data with ETX-312 well tolerated across all dose levels ✅ On track for CTA submission in Q4 2025 Find out more here:

On Friday we presented our preclinical data on ETX-148 in haemophilia at @EAHADnews! It was a great opportunity to learn more about the latest advancements in the space and share our own data with the bleeding disorders community.

We are progressing towards the clinic! 🚀 Find out about our latest progress towards becoming a clinical-stage company and continued development of our HepNet platform in our business update and interim results, published today: https://t.co/U5LNahPwXW #RNAi #AI #Biotech

We are looking forward to presenting new data from our GalOmic therapeutic pipeline at upcoming scientific conferences! Find out more here: https://t.co/YdtVyMJiqe #RNAi #siRNA #MASH #Cardiometabolic #Biotech #AI

Today, #ETX-sponsored Bodhana met with @RachelReevesMP at Downing Street as she prepares to represent England in the upcoming Chess Olympiad at just 9 years old. Good luck from everyone at ETX! #chess #biotech

We are extremely proud of #ETX-sponsored chess prodigy Bodhana who, at just 9 years old, will be the youngest person to represent England in an international sporting competition when she plays in the Chess Olympiad in September! https://t.co/bQMdp6XynN #biotech #chess #AI

We are pleased to announce our final results for the 2023/24 financial year, alongside some exciting pipeline updates! Find out more here: https://t.co/yDbJ5ca0PW $ETX #RNAi #AI #Biotech

Just announced: Lord David Prior has joined as Chair of our Board of Directors! David's insights from his extensive healthcare experience will be invaluable as we progress our GalOmic™ therapies towards the clinic. Find out more: https://t.co/1H4aPj3qh7 #RNAi #AI #Biotech

Just announced: We've raised £28.9m and are planning to delist from London’s #AIM. Proceeds from the fundraise will enable continued progression of our #RNAi assets towards the clinic and accelerated development of our #AI approaches! Find out more: https://t.co/jZ5GImpqzu $ETX

~480M people with #MASH worldwide have no approved treatment options. ETX-312 shows significant therapeutic benefit in a translatable #MASH model alone and in combination with other mechanisms of action including #GLP1 agonists. Learn more: https://t.co/JUPtWuyR10 #biotech #RNAi

In case you missed it: we’re progressing GalOmic #RNAi assets ETX-312 for MASH and ETX-407 for Dry AMD to IND-enabling studies! Find out more about this and other recent progress in our business update: https://t.co/k4irONEI7Z $etx #biotech #MASH #AMD

ETX is advancing its pipeline of GalOmic #RNAi assets towards the clinic, with novel targets identified in-house leveraging HepNet’s proprietary datasets and advanced analytics. Find out more in this morning's business update: https://t.co/k4irONEair $etx #biotech #AI #LLMs

#ETX are proud sponsors of Bodhana Sivanandan who won both the Women’s and Under-12 prizes in the European Blitz Chess Championship last week, finishing top of the English contingent at just 8 years old! What an achievement. https://t.co/8c6ofszwbY #chess #RNAi #AI #biotech

Our CEO Ali Mortazavi is presenting at the LSX Inv€$tival Showcase on Monday! Learn more about our #AI-driven approach to #RNAi medicines on the Healthtech & Techbio stage at 13:45. Reach out at https://t.co/ef2ZbfuFzl to connect during the showcase #biotech #LLM #RNAi

We've announced a collaboration with Arcturis to integrate its Real-World Evidence into HepNet, supporting development of #RNAi therapies for metabolic dysfunction and fatty liver disease. Find out more here: https://t.co/RGd1CF4tYp $etx #biotech #AI #LLMs